医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MetLife Expands Access to Genomics to Help Customers in Asia Prevent and Manage Cancer

2018年12月04日 PM06:53
このエントリーをはてなブックマークに追加


 

HONG KONG

MetLife continues to expand access to new and differentiated health services for customers in Asia to help them better understand and manage their risk of serious illnesses like cancer and determine the best prevention and treatment options.

AmMetLife Insurance Berhad (“AmMetLife”), the strategic partnership between MetLife and AMMB Holdings Berhad (AmBank Group), has launched a first-of-its-kind plan in Malaysia that includes coverage of genomic testing for customers diagnosed with cancer.

The “HCC BoostUp Rider,” attached to the HealthCare Choice Rider, gives customers coverage for a unique combination of medical benefits including genomic testing for cancer, out-patient dengue treatment, home nursing care, and pre-hospitalisation treatment.

“We’re pleased that AmMetLife, is the first insurer to offer a genomic tumour assessment benefit for cancer patients in Malaysia, so they have more information to undertake precision treatment. We already offer genomic testing and precision medicine benefits through some of our solutions in China and pharmacogenomics benefits as a value added service in Korea,” said Joyce Au-Yeung, Regional Head of Health for MetLife in Asia.

To ensure its services and solutions keep pace with medical trends and customers’ evolving needs, MetLife has teamed up with leading medical experts like Dr. Steven Tucker, who specialises in cancer, genomics and precision medicine.

“Genomics is a game changer when it comes to cancer treatment. No two people are the same and consumers everywhere are demanding more personalisation. Medical care is no different and genomics allows us to define the unique characteristics of a patient’s cancer and treat it with precision,” said Dr. Tucker, MetLife’s external medical consultant.

Across Asia, MetLife is steadily building out a combination of holistic insurance solutions and services to help customers better understand how to prevent, diagnose, treat and manage serious illness. In doing so, the company is focused on the five serious illnesses most relevant to Asians: cancer; cardiovascular disease; diabetes; dementia; and mental health.

“Our ambition is to help customers in Asia increase the number of healthy years they live by providing access to differentiated services to help prevent, diagnose, treat, and manage these conditions,” added Au-Yeung.

Note: Genomic testing is done through third parties. Genetic information collected will not be made available to MetLife and its subsidiaries/affiliates.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 countries and holds leading market positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

About AmMetLife

AmMetLife is a strategic partnership between AMMB Holdings Berhad (AmBank Group) and MetLife International Holdings LLC (MetLife). AmMetLife offers a comprehensive range of life assurance and wealth protection solutions distributed through a combination of over 200 AmBank and AmMetLife branded branch offices, in addition to the strength of its authorised life insurance agents nationwide.

The strategic partnership combines the international expertise and financial strength of MetLife with the local strength and reach of AmBank Group to create a customer-centric and modern life assurance solutions provider in Malaysia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005464/en/

CONTACT

Yvette Marmur (Asia): +852 5716-8533 or ymarmur@metlife.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • AMRA、身体組成の非侵襲的測定を実現する磁気共鳴診断ソフトウエアアプリケーションのAMRA® Profilerで米国FDAの承認を取得
  • AMRA用于机体成分无创评估的磁共振诊断软件AMRA® Profiler获得美国FDA核准
  • Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing
  • CDISC and Cohen Veterans Bioscience Announce Release of First Data Standard to Improve Research for Post Traumatic Stress Disorder
  • 武田薬品とニューヨーク科学アカデミーによる”2019 Innovators in Science Award”の受賞者発表について